RESUMEN
The antiemetic effect of a potent and selective neurokinin-1 (NK1) receptor antagonist, FK886 ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochloride), on cisplatin-induced acute and delayed emesis in ferrets was studied. Intravenous administration of FK886 dose-dependently inhibited cisplatin (10 mg/kg)-induced acute emesis with a minimum effective dose (MED) of 0.32 mg/kg. In the same study, oral FK886 administered 8 h prior to cisplatin also dose-dependently inhibited the acute emesis during the 4-h observation period with an MED of 3.2 mg/kg. Further, when given by repeated oral administration of ≥1.6 mg/kg at 12-h intervals, the first dose being administered 1 min before cisplatin, FK886 significantly decreased the number of emetic responses in cisplatin (5 mg/kg)-induced delayed emesis. In the same study, oral FK886 (3.2 mg/kg) repeatedly administrated at 12-h intervals, the first dose being administered 36 h post cisplatin, also significantly attenuated the delayed emesis. Pharmacokinetic data in ferrets showed that plasma FK886 reached a maximum concentration within 0.5 h of administration, suggesting rapid oral absorption. In addition, rapid brain penetration of FK886 was suggested by complete and near complete inhibition of GR73632- and copper sulfate-induced emesis, respectively, by low-dose intravenous FK886 administered shortly before the emetogens. These results suggest that FK886 is an orally available NK1 receptor antagonist which is effective against both the acute and delayed emesis induced by cisplatin. Because of its therapeutic efficacy on the delayed emesis and rapid brain distribution after oral administration, FK886 may have potential as an antiemetic agent that can be used for interventional treatment of chemotherapy-induced delayed emesis.
Asunto(s)
Antieméticos/uso terapéutico , Antineoplásicos/efectos adversos , Cisplatino/efectos adversos , Morfolinas/uso terapéutico , Antagonistas del Receptor de Neuroquinina-1/uso terapéutico , Piperazinas/uso terapéutico , Receptores de Neuroquinina-1/metabolismo , Vómitos/prevención & control , Animales , Antieméticos/farmacología , Barrera Hematoencefálica , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Relación Dosis-Respuesta a Droga , Hurones , Masculino , Morfolinas/metabolismo , Morfolinas/farmacocinética , Morfolinas/farmacología , Antagonistas del Receptor de Neuroquinina-1/farmacología , Piperazinas/metabolismo , Piperazinas/farmacocinética , Piperazinas/farmacología , Vómitos/inducido químicamenteRESUMEN
The pharmacological properties of the novel neurokinin-1 (NK(1)) receptor antagonist FK886, ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochloride), were studied. FK886 potently inhibited the binding of [(125)I]Bolton-Hunter-labeled substance P ([(125)I]BH-SP; 100 pM) to human NK(1) receptors expressed in Chinese hamster ovary (CHO) cells (IC(50)=0.70 nM). It also possessed high affinities for dog, ferret, gerbil and guinea pig NK(1) receptors, but not for rat NK(1) receptor. FK886 was highly selective for the NK(1) receptor, with 250- and >20000-fold selectivity for human NK(1) over NK(2) and NK(3), respectively. Further, it did not inhibit radioligand binding at 54 different sites, including receptors, ion channels and transporters. FK886 inhibited substance P (3.2 nM)-induced inositol phosphate formation in human NK(1) receptor-expressing CHO cells (IC(50)=1.4 nM) without stimulating NK(1) receptors. The antagonism exerted by FK886 against human NK(1) receptor was insurmountable in saturation binding experiments, with both the affinity and B(max) of [(125)I]BH-SP being significantly reduced. After intravenous administration, FK886 (0.01-0.1 mg/kg) dose-dependently inhibited the foot-tapping behavior induced by intracerebroventricular administration of a selective NK(1) receptor agonist, GR73632 (10 pmol), in gerbils, with significant inhibition being observed at doses of 0.032-0.1 mg/kg, indicating excellent brain penetration. The brain penetration of FK886 was further demonstrated by the cerebral distribution of radioactivity after intravenous injection of radiolabeled FK886. Taken together, these results demonstrate that FK886 is a potent, highly selective and centrally active, insurmountable antagonist of the NK(1) receptor, and suggest that FK886 antagonizes various NK(1) receptor-mediated biological effects in the central nervous system.
Asunto(s)
Morfolinas/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Piperazinas/farmacología , Animales , Células CHO , Cricetinae , Cricetulus , Gerbillinae , Humanos , Masculino , Fragmentos de Péptidos/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/metabolismo , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo , Sustancia P/análogos & derivados , Sustancia P/farmacología , Distribución TisularRESUMEN
The antiemetic properties of a novel neurokinin-1 (NK1) receptor antagonist, FK886 ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochloride), were studied in dog models of cisplatin- and apomorphine-induced emesis. Intravenously administered FK886 (0.32-1 mg/kg) significantly inhibited cisplatin-induced acute emesis during the 5-h observation period. Nearly complete inhibition was observed at 1 mg/kg. At an equivalent dose range, orally administered FK886 also significantly inhibited emesis, indicating good oral absorption. Similarly, FK886 inhibited apomorphine-induced emetic responses effectively following both intravenous and oral administration. The effects were long lasting, with 1.6 mg/kg of FK886 completely blocking apomorphine-induced retching and vomiting after a 12-h pretreatment period. Furthermore, FK886 showed rapid onset of antiemetic activity after oral administration. At doses of 0.32 mg/kg or more, a pretreatment time of 0.5 h was sufficient for complete inhibition of apomorphine-induced emetic responses. This fast onset after oral administration was supported by pharmacokinetic data, which demonstrated plasma levels of FK886 after oral administration reached levels similar to those 30 min after intravenous administration. These results suggest that FK886 has excellent antiemetic properties in dogs, and that its rapid-onset and long-lasting properties might make it a promising antiemetic agent.
Asunto(s)
Antieméticos/uso terapéutico , Morfolinas/uso terapéutico , Antagonistas del Receptor de Neuroquinina-1/uso terapéutico , Piperazinas/uso terapéutico , Vómitos/tratamiento farmacológico , Animales , Antieméticos/sangre , Antieméticos/farmacocinética , Apomorfina , Cisplatino , Perros , Femenino , Masculino , Morfolinas/sangre , Morfolinas/farmacocinética , Antagonistas del Receptor de Neuroquinina-1/sangre , Antagonistas del Receptor de Neuroquinina-1/farmacocinética , Piperazinas/sangre , Piperazinas/farmacocinética , Vómitos/inducido químicamente , Vómitos/metabolismoRESUMEN
Temporal variation and fluctuation in environmental contamination in Futaba town and Okuma town, the location of the Fukushima Daiichi Nuclear Power Plant (FDNPP), were evaluated based on a car-borne survey conducted from October 2021 to November 2022. Although the environmental radioactivity in the interim storage facility area (ISF) was higher than that in open areas (i.e., the evacuation order lifted areas in Futaba town and the Specific Reconstruction and Regeneration Base area [SRRB] in Okuma town), only minor temporal changes were seen in the ambient dose and detection rate of radiocesium (the proportion of radiocesium detected points per all measuring points) in those areas, respectively. These findings suggest that the observed variations may result from physical decay and environmental remediation. Resuspension caused by human activities and weather could also affect the detection rate of radiocesium. The annual external effective doses in Futaba town and Okuma town were estimated to be at a limited level (< 1 mSv/year). Nevertheless, to help ensure the safety and future prosperity of residents and communities in the affected areas around the FDNPP, long-term follow-up monitoring of temporal exposure dose levels during the recovery and reconstruction phases is extremely important.
Asunto(s)
Accidente Nuclear de Fukushima , Exposición a la Radiación , Monitoreo de Radiación , Radiactividad , Humanos , Plantas de Energía Nuclear , Exposición a la Radiación/análisis , Japón , Radioisótopos de Cesio/análisisRESUMEN
As the next step that occurred more than one decade after the accident at the Fukushima Dai-ichi Nuclear Power Station (FDNPS), decontamination and demolition have been carried out in the Specified Reconstruction and Revitalization Base (SRRB) of the difficult-to-return zone around the FDNPS. However, the risk of internal exposure among workers due to airborne dust inhalation after building demolition operations has not been sufficiently evaluated. To evaluate the working environment and internal exposure risk due to inhalation in the SRRB of Tomioka town, Fukushima Prefecture, the cesium-137 (137 Cs) radioactivity levels in the airborne dust at building demolition sites were analyzed using gamma spectrometry. The 137 Cs radioactivity levels and resuspension factors of the airborne dust at the subject building sites in the difficult-to-return zone remained at high levels compared with those of the control, which was located in the evacuation order-lifted area in Tomioka town. However, the 137 Cs radioactivity levels did not increase significantly, despite demolition operations that used heavy machinery. In this case, no substantial increases in accident-derived 137 Cs levels due to decontamination and demolition in the SRRB of Tomioka town, Fukushima Prefecture, were observed in the airborne dust samples, which suggests that the 137 Cs radioactivity in the airborne dust is primarily associated with particles that are resuspended by localized winds accompanied by the transfer of construction vehicles as opposed to the decontamination and demolition operations. However, the internal exposure doses due to aspirating airborne dust containing 137 Cs were extremely low compared with the estimated annual effective doses of decontamination workers or the limits recommended by the Japanese government. Additionally, countermeasures such as wearing protective masks could help reduce the on-site inhalation of soil-derived radionuclides. Integr Environ Assess Manag 2022;18:1555-1563. © 2022 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC).
Asunto(s)
Accidente Nuclear de Fukushima , Monitoreo de Radiación , Humanos , Monitoreo de Radiación/métodos , Descontaminación , Radioisótopos de Cesio/análisis , Polvo/análisis , JapónRESUMEN
Tomioka Town is located within a 20-km radius of the Fukushima Daiichi Nuclear Power Station. Radiation dose rates due to radiocesium in residents' living spaces were evaluated from the measurements of ambient dose rates and environmental samples after returning home. The mean ambient dose rates were 0.15-0.18-µSv/h indoors and 0.23-0.26-µSv/h outdoors during 2018 and 2019, and the additional radiation dose rates were calculated to be 1.4 mSv/y in 2018 and 1.1 mSv/y in 2019. Ambient dose equivalent from surface soils within housing sites were estimated to be 0.66 mSv/y in 2018 and 0.54 mSv/y in 2019. Moreover, committed effective doses from local foods were calculated in 19-74 µSv/y for children and 39-100 µSv/y for adults during 2018 and 2019. These findings suggest that current radiation exposure doses have been controlled at the levels close to the public dose limit (1 mSv/y) in residents' living spaces.
Asunto(s)
Accidente Nuclear de Fukushima , Exposición a la Radiación , Monitoreo de Radiación , Adulto , Niño , Vivienda , Humanos , Japón , Dosis de Radiación , Exposición a la Radiación/análisis , SueloRESUMEN
In recent years, Japan has suffered serious damage due to natural disasters such as earthquakes, heavy rains due to tropical storms (typhoons) and localized downpours. To assess the chronological changes in the attenuation of external exposure doses and environmental radiation contamination due to the rainfall associated with typhoons and heavy rains during October to December 2019 in Fukushima, we measured environmental radiation levels in forest areas along the Mt Okura hiking trail in Tomioka Town, Fukushima Prefecture, near the Fukushima Daiichi Nuclear Power Station. We confirmed that (1) current ambient dose rates of 0.38-0.95 µSv/h in most forest areas were 79.9-84.7% higher than in residential areas; (2) the number of sites along the hiking trail where 137Cs was detected was limited (1.1-4.7%); and (3) individual dose rates of 0.21-0.34 µSv/h were lower than ambient dose rates. These findings suggest that radiocesium has remained stable in natural forests that have not been decontaminated even though current levels are low, despite the occurrence of heavy rainfall associated with Super Typhoon Hagibis in 2019 and localized downpours. Hiking while managing exposure to environmental contamination using a personal dosimeter may be the safest model for spending time of leisure activities.
Asunto(s)
Radioisótopos de Cesio/análisis , Bosques , Accidente Nuclear de Fukushima , Contaminantes Radiactivos del Suelo/análisis , Tormentas Ciclónicas , Japón , Monitoreo de Radiación , LluviaRESUMEN
Temporal variations in ambient dose rates in a restricted area designated as "difficult-to-return" for residents of Tomioka Town, Fukushima Prefecture were evaluated in a car-borne survey during 2018-2019. The median dose rates in the "Decontaminated area" in the difficult-to-return zone decreased rapidly from 1.0 µSv/h to 0.32 µSv/h; however, the median dose rates in the "Non-decontaminated area" and "Radioactive waste storage area" fluctuated between 1.1-1.4 µSv/h and 0.46-0.61 µSv/h, respectively. The detected rate of the cesium-137 (137Cs) (137Cs-detected points per all measuring points) in the "Decontaminated area" also decreased rapidly from 64% to 6.7%, accompany with decreasing in ambient dose rates. On the other hand, the detection of 137Cs in the "Radioactive waste storage area" and "Non-decontaminated area" decreased from 53% to 17% and 93% to 88%, respectively. We confirmed that the dose rates in the Decontaminated area dramatically decreased due to decontamination work aiming to help residents return home. Moreover, the estimated external exposure dose of workers during the present survey was 0.66 mSv/y in the Decontaminated area and 0.55 mSv/y in the Radioactive waste storage area, respectively. This case of Tomioka Town within the "difficult-to-return zone" may be the first reconstruction model for evaluating environmental contamination and radiation exposure dose rates due to artificial radionuclides derived from the nuclear disaster.
Asunto(s)
Restauración y Remediación Ambiental , Accidente Nuclear de Fukushima , Plantas de Energía Nuclear , Monitoreo de Radiación , Radioisótopos de Cesio/análisis , Descontaminación , Humanos , Japón , Dosis de Radiación , Exposición a la Radiación/análisis , Residuos RadiactivosRESUMEN
On 1 April 2017, six years have passed since the Fukushima Daiichi Nuclear Power Station (FDNPS) accident, and the Japanese government declared that some residents who lived in Tomioka Town, Fukushima Prefecture could return to their homes. We evaluated environmental contamination and radiation exposure dose rates due to artificial radionuclides in the livelihood zone of residents (living space such as housing sites), including a restricted area located within a 10-km radius from the FDNPS, immediately after residents had returned home in Tomioka town. In areas where the evacuation orders had been lifted, the median air dose rates were 0.20 µSv/h indoors and 0.26 µSv/h outdoors, and the radiation exposure dose rate was 1.6 mSv/y. By contrast, in the "difficult-to-return zone," the median air dose rate was 2.3 µSv/h (20 mSv/y) outdoors. Moreover, the dose-forming artificial radionuclides (radiocesium) in the surface soil were 0.018 µSv/h (0.17 mSv/y) in the evacuation order-lifted areas and 0.73 µSv/h (6.4 mSv/y) in the difficult-to-return zone. These findings indicate that current concentrations of artificial radionuclides in soil samples have been decreasing in the evacuation order-lifted areas of Tomioka town; however, a significant external exposure risk still exists in the difficult-to-return zone. The case of Tomioka town is expected to be the first reconstruction model including the difficult-to-return zone.
Asunto(s)
Accidente Nuclear de Fukushima , Exposición a la Radiación/análisis , Humanos , Japón , Dosis de Radiación , Monitoreo de RadiaciónRESUMEN
In this study, we detected genes sensitive to an histone deacetylase inhibitor, FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo-[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, depsipeptide] in vitro and identified marker genes to predict sensitivity to FK228 in vivo using Affymetrix GeneChip. Three percent of genes (205/7070) were sensitive to FK228 in vitro, 105 and 100 genes, were up- and down-regulated, respectively, by FK228. Commonly up-regulated genes included p21(WAF1/Cip1), interleukin-8 (IL-8), histone family, JunB, caspase 9, mitogen-activated protein kinase phosphatase 1 (MKP-1) and mitogen-activated protein kinase (MAPK) family, and commonly down-regulated genes included cyclin A and MAPK family. One percent of genes (76/7070) showed native differences in patterns of expression, when FK228-sensitive (PC-3 prostate and SC-6-JCK (SC-6) stomach) and FK228-resistant (ACHN and A-498 renal) tumors implanted in BALB/c nu/nu mice were compared. Twenty-seven and forty nine of those genes were expressed at high or low levels, respectively, in FK228-sensitive tumors. Caspase 9 and MKP-1 genes showed distinct differences in patterns of expression between FK228-sensitive and resistant tumors and have been known to have roles in apoptosis and chromatin remodeling. The expression of caspase 9 gene was higher in FK228-sensitive tumors and the expression of MKP-1 gene was higher in FK228-resistant tumors. Caspase 9 and MKP-1 genes in the other FK228-sensitive tumors had the same patterns of expression as they did in PC-3 and SC-6 tumors. Our results present profiles of gene expression related to FK228 and marker genes to predict sensitivity to FK228, such as caspase 9 and MKP-1 genes.
Asunto(s)
Depsipéptidos/farmacología , Inhibidores Enzimáticos/farmacología , Inhibidores de Histona Desacetilasas , Animales , Caspasa 9 , Caspasas/genética , Proteínas de Ciclo Celular/genética , Línea Celular Tumoral , Fosfatasa 1 de Especificidad Dual , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Proteínas Inmediatas-Precoces/genética , Masculino , Ratones , Ratones Desnudos , Análisis de Secuencia por Matrices de Oligonucleótidos , Fosfoproteínas Fosfatasas/genética , Proteína Fosfatasa 1 , Proteínas Tirosina Fosfatasas/genética , Factores de TiempoRESUMEN
In this study, we examined the effects of FK228 (FR901228, depsipeptide) on tumor growth and expression of p21 and c-myc genes in vivo. FK228 induced the expression of p21 mRNA and decreased c-myc mRNA in tumor xenograft sensitive to FK228. However, FK228 did not sufficiently modulate the expression of p21 mRNA and increased the expression of c-myc in tumor xenograft less sensitive to FK228. The modulation of p21 and/or c-myc genes may be critical for the marked antitumor activity of FK228 in vivo.
Asunto(s)
Ciclinas/biosíntesis , Depsipéptidos , Inhibidores Enzimáticos/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Inhibidores de Histona Desacetilasas , Proteínas de Neoplasias/antagonistas & inhibidores , Péptidos Cíclicos/farmacología , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Proteínas Proto-Oncogénicas c-myc/biosíntesis , Acetilación/efectos de los fármacos , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Neoplasias de las Glándulas Suprarrenales/metabolismo , Neoplasias de las Glándulas Suprarrenales/patología , Animales , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Células Renales/metabolismo , Carcinoma de Células Renales/patología , Carcinoma de Células Pequeñas/metabolismo , Carcinoma de Células Pequeñas/patología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/genética , Inhibidores Enzimáticos/uso terapéutico , Genes myc , Humanos , Neoplasias Renales/metabolismo , Neoplasias Renales/patología , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/genética , Péptidos Cíclicos/uso terapéutico , Feocromocitoma/metabolismo , Feocromocitoma/patología , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , ARN Mensajero/biosíntesis , ARN Neoplásico/biosíntesis , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Células Tumorales Cultivadas/trasplante , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14- oxa-1,11-diazatraacylo[7.4.1.0(2.7).0(10.2)]-tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, and mitomycin C (MMC) on survival time of mice bearing B16BL6 melanoma and Lewis lung carcinoma (LLC), induced by intravenous inoculation of the tumor, were investigated. Treatment with FK317 resulted in a significant prolongation of survival time in both tumor models. Four of ten mice bearing B16BL6 were disease-free following FK317 treatment. In contrast, MMC was not effective in prolonging survival time. Overall, this study demonstrated that FK317 shows more potent survival extension in mice bearing B16BL6 and LLC than MMC, suggesting that FK317 may have therapeutic utility for cancer chemotherapy.
Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Pulmonar de Lewis/tratamiento farmacológico , Melanoma Experimental/tratamiento farmacológico , Oxazinas/uso terapéutico , Animales , Evaluación de Medicamentos , Femenino , Ratones , Ratones Endogámicos , Mitomicina/uso terapéutico , Análisis de SupervivenciaRESUMEN
FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo-[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, depsipeptide] is a novel histone deacetylase inhibitor that shows therapeutic efficacy in Phase I trials of patients with malignant lymphoma. However, its mechanism of action has not been characterized. In this study, we examined the in vitro and in vivo effects of FK228 on human lymphoma U-937 cells. FK228 very strongly inhibited the growth of U-937 cells with an IC(50) value of 5.92 nM. In a scid mouse lymphoma model, mice treated with FK228 once or twice a week survived longer than control mice, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). Remarkably, 2 out of 12 mice treated with FK228 (0.56 mg/kg once or twice a week) survived past the observation period of 60 days. The apoptotic population of U-937 cells time-dependently increased to 37.7% after 48 hr of treatment with FK228. In addition, FK228 induced G1 and G2/M arrest and the differentiation of U-937 cells to the CD11b(+)/CD14(+) phenotype. Expression of p21(WAF1/Cip1) and gelsolin mRNA increased up to 654- and 152-fold, respectively, after 24hr of treatment with FK228. FK228 caused histone acetylation in p21(WAF1/Cip1) promoter regions, including the Sp1-binding sites. In conclusion, (i) FK228 prolonged the survival time of scid mice in a lymphoma model, and (ii) the beneficial effects of FK228 on human lymphoma may be exerted through the induction of apoptosis, cell cycle arrest, and differentiation via the modulation of gene expression by histone acetylation.
Asunto(s)
Antibacterianos/farmacología , Antibióticos Antineoplásicos/farmacología , Apoptosis , Depsipéptidos , Inhibidores de Histona Desacetilasas , Péptidos Cíclicos , Acetilación , Animales , Antibacterianos/uso terapéutico , Antibióticos Antineoplásicos/uso terapéutico , Ciclo Celular/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Colecalciferol/farmacología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/biosíntesis , Ciclinas/genética , Modelos Animales de Enfermedad , Gelsolina/biosíntesis , Gelsolina/genética , Histonas/metabolismo , Humanos , Leucemia/patología , Linfoma/tratamiento farmacológico , Linfoma/patología , Ratones , Ratones SCID , Trasplante de Neoplasias , Regiones Promotoras Genéticas/efectos de los fármacos , Regiones Promotoras Genéticas/genética , ARN Mensajero/biosíntesis , ARN Mensajero/efectos de los fármacos , Tretinoina/farmacología , Células U937 , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
UNLABELLED: It has been recently demonstrated that histone deacetylase inhibitors inhibit angiogenesis, but their mechanism of action has not been characterized well. In this study, we examined the in vitro and in vivo effects of FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo-[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, depsipeptide], an HDAC inhibitor, on the expression of angiogenesis factors in FK228-sensitive PC-3 prostate and FK228-resistant ACHN renal cancer cells. FK228 suppressed the expression of VEGF mRNA in PC-3 cells, but not in ACHN cells. FK228 also suppressed the expression of basic fibroblast growth factor (bFGF) mRNA in both PC-3 and ACHN cells. Under conditions of hypoxia, FK228 suppressed the expression of VEGF mRNA without modulating the expression of hypoxia-inducible factor-1 alpha mRNA in PC-3 cells. FK228 induced the highest acetylation of histone H3 and H4 in the P2 region of the VEGF promoter, which includes the hypoxia-inducible factor-1 alpha binding site that plays an important role in regulating the expression of VEGF gene. Moreover, FK228 reduced the amount of VEGF and bFGF protein, and their mRNA levels in PC-3 xenograft implanted in nude mice, but did not reduce them in ACHN xenograft. IN CONCLUSION: (i) FK228 showed a suppressive effect on the expression of angiogenesis factors, such as VEGF and bFGF, in PC-3 xenograft but not in ACHN xenograft, which suggests that the effect on the expression of angiogenesis factors is important for the antitumor efficacy of FK228; (ii) FK228 caused histone acetylation of the VEGF promoter regions, which may contribute to the suppression of VEGF gene expression.
Asunto(s)
Antibióticos Antineoplásicos/farmacología , Depsipéptidos , Factores de Crecimiento Endotelial/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Inhibidores de Histona Desacetilasas , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Linfocinas/metabolismo , Péptidos Cíclicos/farmacología , Factores de Transcripción , Acetilación/efectos de los fármacos , Inductores de la Angiogénesis , Animales , Antibióticos Antineoplásicos/uso terapéutico , Cromatina/metabolismo , Proteínas de Unión al ADN/metabolismo , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Expresión Génica/efectos de los fármacos , Factor 1 Inducible por Hipoxia , Subunidad alfa del Factor 1 Inducible por Hipoxia , Masculino , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Proteínas Nucleares/metabolismo , Péptidos Cíclicos/uso terapéutico , Regiones Promotoras Genéticas , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Células Tumorales Cultivadas , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
We evaluated the antiemetic activity of resiniferatoxin, an ultrapotent capsaicin analogue, on cisplatin- and apomorphine-induced emesis in dogs, and on cisplatin-induced acute and delayed emesis in ferrets. In the dog, resiniferatoxin (10 microg/kg, s.c.) 30 min before the injection of cisplatin markedly prevented acute emesis induced by cisplatin. When animals were given resiniferatoxin (10 microg/kg, s.c.) 24 h prior to cisplatin, the emesis was still inhibited, but not significantly. Resiniferatoxin (10 microg/kg, s.c.) 30 min before the administration of apomorphine also significantly reduced the emetic responses induced by apomorphine in dogs. In the ferret, resiniferatoxin (10 microg/kg, s.c.) 30 min prior to cisplatin completely inhibited acute emesis caused by cisplatin (10 mg/kg, i.p.). When ferrets were given resiniferatoxin (10 microg/kg, s.c.) 16 h prior to cisplatin, the emesis was still significantly inhibited. Cisplatin (5 mg/kg, i.p.) induced both acute (0-24 h) and delayed (24-72 h) phase emesis, and a single injection of resiniferatoxin (10 microg/kg, s.c.) at 36 h after cisplatin significantly reduced subsequent emetic responses during the 36-72 h period. These results suggest that resiniferatoxin-related vanilloids may be useful drugs against both acute and delayed emesis induced by cancer chemotherapy.
Asunto(s)
Antineoplásicos/administración & dosificación , Cisplatino/administración & dosificación , Diterpenos/farmacología , Vómitos/prevención & control , Enfermedad Aguda , Animales , Antineoplásicos/toxicidad , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/toxicidad , Apomorfina/administración & dosificación , Apomorfina/toxicidad , Cisplatino/toxicidad , Perros , Femenino , Hurones , Masculino , Factores de Tiempo , Vómitos/inducido químicamenteRESUMEN
To investigate whether gastrointestinal lipase inhibition reduces the progression of a western-type diet induced atherosclerosis, male apolipoprotein-E knockout (apoE KO) mice were administered orlistat ((S)-1-[[(S, 2S, 3S)-3-hexyl-4-oxo-2-oxetanyl] methyl]dodecyl-(S)-2-formamido-4-methylvalerate) mixed with a western-type diet for 8 weeks. Orlistat significantly reduced plasma triglyceride levels, but not total cholesterol levels, at 4 and 8 weeks of treatment. Increase in plasma triglyceride levels after oral olive oil loading in the mice fed a western-type diet was significantly suppressed in the orlistat treated group at 4 weeks of treatment. After 8 weeks treatment, atherosclerotic lesion area in the aorta of the orlistat treated group was significantly smaller than that of the control group. These results suggest that gastrointestinal lipase inhibition reduces the progression of atherosclerosis through a triglyceride-lowering effect, via inhibition of fat absorption.
Asunto(s)
Arteriosclerosis/tratamiento farmacológico , Colesterol en la Dieta/efectos adversos , Dieta Aterogénica , Tracto Gastrointestinal/enzimología , Lactonas/uso terapéutico , Lipasa/antagonistas & inhibidores , Animales , Apolipoproteínas E/deficiencia , Arteriosclerosis/sangre , Arteriosclerosis/enzimología , Colesterol en la Dieta/farmacología , Lactonas/farmacología , Lipasa/metabolismo , Masculino , Ratones , Ratones Noqueados , Orlistat , Triglicéridos/sangreRESUMEN
The aim of the present study was to determine the role of tachykinin in the micturition reflex in guinea pigs. We investigated the effects of tachykinin NK(1) receptor antagonists, GR205171 ([2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl-piperidin-3S-yl)-amine), CP99994 ((+), (2R, 3R)-3-(2-methoxybenzyl-amino)-2-phenylpiperidine) and FK888 (N(2)-[(4R)-4-hydroxy-1-(1-methyl-1H-indol-3-yl) carbonyl-L-prolyl]-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L-alaninamide), the tachykinin NK(2) receptor antagonist, SR48968 ((+)-N-methyl-[4-(4-acetylamino-4-phenyl piperidino)-2-(3, 4-dichloro-phenyl)butyl] benzamide), and the tachykinin NK(3) receptor antagonist, SB223412 ((S)-(-)-N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide) on rhythmic bladder contraction. GR205171 and CP99994 but not SR48968 or SB223412 reduced bladder contraction frequency. FK888 inhibited the frequency very slightly at the highest dose tested. The distribution of tachykinin NK(1) receptor antagonists to the central nervous system after intravenous administration was examined using an ex vivo binding assay. GR205171 was distributed to the brain and spinal cord, but the tachykinin NK(1) receptor antagonist, FK888, was not. These results suggest that tachykinin NK(1) receptors, which are located in the central nervous system, play an important role in micturition in guinea pigs.
Asunto(s)
Cobayas/fisiología , Receptores de Neuroquinina-1/fisiología , Micción/fisiología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Células CHO , Cateterismo , Cricetinae , Dipéptidos/administración & dosificación , Dipéptidos/sangre , Dipéptidos/farmacocinética , Relación Dosis-Respuesta a Droga , Humanos , Indoles/administración & dosificación , Indoles/sangre , Indoles/farmacocinética , Inyecciones Intravenosas , Radioisótopos de Yodo/metabolismo , Masculino , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Antagonistas del Receptor de Neuroquinina-1 , Piperidinas/administración & dosificación , Piperidinas/metabolismo , Piperidinas/farmacocinética , Ensayo de Unión Radioligante , Médula Espinal/química , Médula Espinal/efectos de los fármacos , Médula Espinal/metabolismo , Sustancia P/antagonistas & inhibidores , Sustancia P/metabolismo , Succinimidas/antagonistas & inhibidores , Succinimidas/metabolismo , Tetrazoles/administración & dosificación , Tetrazoles/metabolismo , Tetrazoles/farmacocinética , Extractos de Tejidos/química , Extractos de Tejidos/farmacología , Transfección/métodos , Vejiga Urinaria/fisiología , Micción/efectos de los fármacosRESUMEN
We evaluated the antiemetic effect of zacopride, a potent 5-HT3-receptor antagonist with 5-HT4-receptor agonist properties, on delayed emesis caused by cisplatin (5 mg/kg, i.p.) in ferrets, compared with granisetron, a selective 5-HT3-receptor antagonist. Multiple intravenous injections of zacopride at 1 mg/kg, a dose that completely inhibited acute emesis caused bycisplatin (10 mg/kg, i.v.), significantly reduced delayed emesis. Granisetron (3.2 mg/kg) also reduced delayed emesis but this failed to reach statistical significance. The present study suggests that a combined 5-HT3-receptor antagonist/5-HT4-receptor agonist, like zacopride, may be useful against both acute and delayed emesis induced by cancer chemotherapy.
Asunto(s)
Antieméticos/farmacología , Antineoplásicos/efectos adversos , Benzamidas/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Cisplatino/efectos adversos , Antagonistas de la Serotonina/farmacología , Vómitos/prevención & control , Animales , Quimioterapia Combinada , Hurones , Granisetrón/farmacología , Masculino , Factores de Tiempo , Vómitos/inducido químicamenteRESUMEN
Microsomal triglyceride transfer protein (MTP) is essential for the synthesis of both chylomicron in the intestine and very low-density lipoprotein in the liver. An MTP inhibitor, (2S)-2-cyclopentyl-2-[4-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1S)-2-hydroxy-1-phenylethyl]ethanamide (implitapide), has been shown to suppress atherosclerosis in apolipoprotein E knockout (apoE KO) mice. To elucidate the antiatherosclerotic mechanisms of implitapide in the mice, we examined the effects on plasma lipid levels, triglyceride (TG) elevation after oral fat loading, and development of atherosclerosis in apoE KO mice fed a Western-type diet. Implitapide at a dosage of approximately 3.2 mg/kg/day significantly reduced both total cholesterol and TG levels during the 8-week treatment period. In addition, implitapide significantly inhibited the increase in plasma TG levels after oral olive oil loading tests conducted after 4 weeks of treatment. After the treatment, implitapide significantly suppressed the atherosclerotic lesion area by 83% compared with a control group. These results provide direct evidence that the antiatherosclerotic effects of implitapide in apoE KO mice are associated with the inhibition of postprandial TG elevation, in addition to the reduction of both plasma total cholesterol and TG levels.
Asunto(s)
Apolipoproteínas E/deficiencia , Arteriosclerosis/sangre , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/sangre , Dieta Aterogénica , Indoles/uso terapéutico , Piridinas/uso terapéutico , Triglicéridos/antagonistas & inhibidores , Triglicéridos/sangre , Animales , Aorta Torácica/efectos de los fármacos , Aorta Torácica/metabolismo , Apolipoproteínas E/genética , Arteriosclerosis/prevención & control , Grasas de la Dieta/administración & dosificación , Indoles/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Periodo Posprandial/efectos de los fármacos , Periodo Posprandial/fisiología , Piridinas/farmacologíaRESUMEN
We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 microg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate.